


**In the claims:**


1. (Previously Presented) A method of treatment of atherosclerosis, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and/or in-stent-stenosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound, said compound selected from the group having a formula:




or pharmaceutically acceptable salts thereof, wherein:

(i)  $\text{A}_1$  and  $\text{A}_2$  are each independently selected from the group consisting of  $\text{CH}_2$  and  $\text{C}=\text{O}$ , at least one of  $\text{A}_1$  and  $\text{A}_2$  being  $\text{CH}_2$ ;


(ii)  $\text{R}_1$  and  $\text{R}_2$  are each independently selected from the group consisting of an alkyl chain having 1-27 carbon atoms and




wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



Z is selected from the group consisting of:




whereas  $R_4$  is an alkyl,

at least one of  $R_1$  and  $R_2$  being said ; and


(iii)  $R_3$  is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiopin and phosphoinisitol.

2. (Original) The method of claim 1, wherein each of  $A_1$  and  $A_2$  is  $CH_2$ .

3. (Original) The method of claim 1, wherein  $R_1$  is an alkyl chain having 1-27 carbon atoms and  $R_2$  is




wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



, -OH, -H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:



whereas  $R_4$  is an alkyl.

4. (Original) The method of claim 3, wherein each of  $A_1$  and  $A_2$  is  $CH_2$ .

5. (Original) The method of claim 1, wherein said compound is administered via mucosal administration.


6. (Original) The method of claim 1, wherein administration of said compound is nasal, oral or intra- peritoneal administration.

7. (Original) The method of claim 1, wherein administration of said compound reduces immune reactivity to oxidized LDL in said subject.

8. (Currently Amended) The method of claim 1, wherein said compound is administered in addition to a therapeutically effective amount of at least one ~~additional compound selected from the group consisting of statins, mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens.~~


9-19. (Canceled)

20. (Previously Presented) A method of treatment of atherosclerosis, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and/or in-stent-stenosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound, said compound selected from the group having a formula:




or pharmaceutically acceptable salts thereof, wherein:

- (i)  $\text{A}_1$  and  $\text{A}_2$  are each independently selected from the group consisting of  $\text{CH}_2$  and  $\text{C}=\text{O}$ , at least one of  $\text{A}_1$  and  $\text{A}_2$  being  $\text{CH}_2$ ;
- (ii)  $\text{R}_1$  is selected from the group consisting of an alkyl chain having 1-27 carbon atoms and




wherein X is an alkyl chain having 1-24 carbon atoms,

Y is selected from the group consisting of:




Z is selected from the group consisting of:




whereas R<sub>4</sub> is an alkyl;


(iii) R<sub>2</sub> is



wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



Z is selected from the group consisting of:




whereas R<sub>4</sub> is an alkyl; and


(iv) R<sub>3</sub> is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiolipin and phosphoinositol.

21. (Previously Presented) The method of claim 20, wherein each of A<sub>1</sub> and A<sub>2</sub> is CH<sub>2</sub>.

22. (Previously Presented) The method of claim 20, wherein R<sub>1</sub> is an alkyl chain having 1-27 carbon atoms and R<sub>2</sub> is




wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



-OH, -H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:



whereas R<sub>4</sub> is an alkyl.

23. (Previously Presented) The method of claim 22, wherein each of A<sub>1</sub> and A<sub>2</sub> is CH<sub>2</sub>.

24. (Previously Presented) The method of claim 20, wherein said compound is administered via mucosal administration.

25. (Previously Presented) The method of claim 20, wherein administration of said compound is nasal, oral or intra- peritoneal administration.

26. (Previously Presented) The method of claim 20, wherein administration of said compound reduces immune reactivity to oxidized LDL in said subject.

27. (Currently Amended) The method of claim 20, wherein said compound is administered in addition to a therapeutically effective amount of at least one ~~additional compound selected from the group consisting of statins, mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens.~~